MedTrace Logo

Adding Sitagliptin or Pioglitazone to Type 2 Diabetes Mellitus Insufficiently Controlled With Metformin and Sulfonylurea

NCT01195090 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 120

Last updated 2012-10-10

Study results available
· View outcomes & findings →

Summary

This 24-weeks study will to compare the glycemic efficacy and safety of sitagliptin with pioglitazone in patients with type 2 diabetes who had inadequate glycemic control despite dual therapy with metformin and a sulfonylurea.

Conditions

Interventions

DRUG

Sitagliptin

add sitagliptin100mg/d to pre-study OADs

DRUG

pioglitazone

add pioglitazone 30mg/d to pre-study OADs

Sponsors & Collaborators

  • Mackay Memorial Hospital

    collaborator OTHER

  • Sung-Chen Liu

    lead OTHER

Principal Investigators

  • Sung-Chen Liu, MD · Division of Endocrinology and Metabolism, Department of Internal Medicine, Mackay Memorial Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-10-31
Primary Completion
2011-10-31
Completion
2012-04-30

Countries

  • Taiwan

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01195090 on ClinicalTrials.gov